Now, a number of more specific, small-molecule RIPK1 inhibitors have been developed by Glaxo-Smith Kline (GSK), Sanofi/Denali (DNL), Takeda, and Genentech, which are either undergoing pre-clinical testing or have entered early-phase clinical trials, including the benzoxazepinone GSK2982772 for the treatment of psoriasis, ulcerative colitis (UC), and RA, and brain-penetrant DNL747 for the treatment of the neurodegenerative disease Amyotrophic Lateral Sclerosis (ALS) [94,101,102]. This evidence concerns the gene RIPK1 and rheumatoid arthritis.